Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

Video

In Partnership With:

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Clinical trial data of the combination demonstrates that two non-cross reactive agents can perform synergistically, Lonial explains. Studies have shown that in the relapsed/refractory setting, pomalidomide and dexamethasone demonstrated an overall response rate (ORR) of 30%, while single-agent daratumumab elicited an ORR of 30% in a similar setting.

Together, pomalidomide and daratumumab demonstrated an ORR of approximately 70%, and a significant number of patients achieved a very good partial response or better, Lonial adds. The combination enhances the immune system's ability to make daratumumab more effective, he says.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,